SCHEMBL103196

SCHEMBL103196

Cc1nc(Br)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14573610 0.82
SCHEMBL67456 0.73
SCHEMBL128316 0.71
SCHEMBL586988 0.71 CYP19A1 (0.34)
SCHEMBL2487462 0.71
SCHEMBL24359598 0.71 GAA (0.52)
Hydrochloric Acid SCHEMBL11308925 0.69
Ammonia Solution, Strong SCHEMBL28692741 0.69
Iodide SCHEMBL27887241 0.69
Bromide SCHEMBL27485582 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 518 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US claimed
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 US disclosed
WO-2026101959-A1 HETEROAROMATIC INDOLESULFONAMIDES SEED THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
CN-122029158-A EGFR inhibitors 缆图药品公司 2026-05-12 CN disclosed
EP-4735430-A1 MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2026-05-06 EP disclosed
EP-4695242-A1 NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF Meta Pharmaceuticals (HK) Limited (HK) 2026-02-18 EP disclosed
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 EP disclosed
EP-4650002-A1 ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) Ludwig-Maximilians-Universität (DE) 2025-11-19 EP disclosed
US-12459923-B2 Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2025-11-04 US disclosed
WO-2025215110-A1 NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS LES LABORATOIRES SERVIER (FR) 2025-10-16 WO disclosed
EP-1364040-A2 DEGRADATION OF EPOTHILONES AND ETHYNYL SUBSTITUTED EPOTHILONES Gesellschaft für biotechnologische Forschung mbH (GBF) (DE) 2003-11-26 EP disclosed
WO-2003087104-A1 HETEROCYCLIC COMPOUNDS ASTRAZENECA AB (SE) 2003-10-23 WO disclosed
US-6603015-B2 Antitumor agents; anticancer agents; malaria; Alzheimer's disease UNIVERSITY OF KANSAS 2003-08-05 US disclosed
US-20020165415-A1 SYNTHESIS OF EPOTHILONES GEORG GUNDA I (US) 2002-11-07 US disclosed
US-20020156289-A1 Synthesis of epothilones THE UNIVERSITY OF KANSAS 2002-10-24 US disclosed
US-6457303-B1 WIDE VARIETY OF CORRESPONDING ANALOGS AND HOMOLOGS. THE UNIVERSITY OF KANSAS 2002-10-01 US disclosed
WO-2002072858-A2 DEGRADATION OF EPOTHILONES AND ETHYNYL SUBSTITUTED EPOTHILONES GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) 2002-09-19 WO disclosed
US-6211412-B1 REACTING BETA-KETO ESTER WITH HYDROGENATING AGENT IN PRESENCE OF ASYMMETRIC ORGANOMETALLIC MOLECULAR CATALYST COMPRISING METAL ATOM HAVING ONE OR MORE CHIRAL LIGANDS COUPLED THERETO, CONVERTING HYDROXYESTER FORMED TO EPOTHILONE PRECURSOR THE UNIVERSITY OF KANSAS 2001-04-03 US disclosed
WO-2000058254-A1 SYNTHESIS OF EPOTHILONES THE UNIVERSITY OF KANSAS (US) 2000-10-05 WO disclosed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 US disclosed